|
HY-13104-5mg
|
MedChemexpress LLC
|
MRS 2578 [CAS 711019-86-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-13104-50mg
|
MedChemexpress LLC
|
MRS 2578 [CAS 711019-86-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-13104-1mL
|
MedChemexpress LLC
|
MRS 2578 [CAS 711019-86-2] (10mM in DMSO)
|
|
COVID-19-immunoregulation
|
|
|
HY-108658-10mg
|
MedChemexpress LLC
|
MRS2500 (tetraammonium) [CAS 630103-23-0]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-108658-2mg
|
MedChemexpress LLC
|
MRS2500 (tetraammonium) [CAS 630103-23-0]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-108658-5mg
|
MedChemexpress LLC
|
MRS2500 (tetraammonium) [CAS 630103-23-0]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-153356-10mg
|
MedChemexpress LLC
|
MRT-2359 [CAS 2803881-11-8]
|
|
Cancer-programmed cell death
|
|
|
HY-153356-100mg
|
MedChemexpress LLC
|
MRT-2359 [CAS 2803881-11-8]
|
|
Cancer-programmed cell death
|
|
|
HY-153356-5mg
|
MedChemexpress LLC
|
MRT-2359 [CAS 2803881-11-8]
|
|
Cancer-programmed cell death
|
|
|
HY-153356-50mg
|
MedChemexpress LLC
|
MRT-2359 [CAS 2803881-11-8]
|
|
Cancer-programmed cell death
|
|
|
HY-139611-1mg
|
MedChemexpress LLC
|
MRTX-1719 [CAS 2630904-45-7]
|
|
Cancer-programmed cell death
|
|
|
HY-139611-10mg
|
MedChemexpress LLC
|
MRTX-1719 [CAS 2630904-45-7]
|
|
Cancer-programmed cell death
|
|
|
HY-139611-25mg
|
MedChemexpress LLC
|
MRTX-1719 [CAS 2630904-45-7]
|
|
Cancer-programmed cell death
|
|
|
HY-139611-5mg
|
MedChemexpress LLC
|
MRTX-1719 [CAS 2630904-45-7]
|
|
Cancer-programmed cell death
|
|
|
HY-125232-10mg
|
MedChemexpress LLC
|
MS645 [CAS 2250091-96-2]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-125232-100mg
|
MedChemexpress LLC
|
MS645 [CAS 2250091-96-2]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-125232-25mg
|
MedChemexpress LLC
|
MS645 [CAS 2250091-96-2]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-125232-5mg
|
MedChemexpress LLC
|
MS645 [CAS 2250091-96-2]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-125232-50mg
|
MedChemexpress LLC
|
MS645 [CAS 2250091-96-2]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-125232-1mL
|
MedChemexpress LLC
|
MS645 [CAS 2250091-96-2] (10mM in DMSO)
|
|
Neuroscience-Neuromodulation
|
|
|
HY-148334-10mg
|
MedChemexpress LLC
|
MS8815 [CAS 2855085-25-3]
|
|
Cancer-programmed cell death
|
|
|
HY-148334-100mg
|
MedChemexpress LLC
|
MS8815 [CAS 2855085-25-3]
|
|
Cancer-programmed cell death
|
|
|
HY-148334-25mg
|
MedChemexpress LLC
|
MS8815 [CAS 2855085-25-3]
|
|
Cancer-programmed cell death
|
|
|
HY-148334-5mg
|
MedChemexpress LLC
|
MS8815 [CAS 2855085-25-3]
|
|
Cancer-programmed cell death
|
|
|
HY-148334-50mg
|
MedChemexpress LLC
|
MS8815 [CAS 2855085-25-3]
|
|
Cancer-programmed cell death
|
|
